Printer Friendly

ONCURIOUS passes European Commission Orphan Medicinal Product designation for TB-403 for medulloblastoma.

M2 PHARMA-January 17, 2017-ONCURIOUS passes European Commission Orphan Medicinal Product designation for TB-403 for medulloblastoma


Oncology company ONCURIOUS NV reported on Tuesday the receipt of the European Commission orphan drug designation for TB-403 for medulloblastoma.

The company said TB-403 is a humanized monoclonal antibody against placental growth factor (PlGF). PlGF is expressed in several types of cancer, including medulloblastoma. In medulloblastoma patients, high expression of the PlGF receptor neuropilin 1 has been shown to correlate with poor overall patient survival.

EC approval follows a prior in-depth review and positive opinion on the TB-403 drug candidate by the EMA Committee for Orphan Medicinal Products (COMP).

Currently, TB-403 is being evaluated in a Phase I/IIa clinical trial for treatment of medulloblastoma, a rare life-threatening brain tumor that mainly affects children.

This clinical trial is being conducted in partnership with the Neuroblastoma and Medulloblastoma Translational Research Consortium (NMTRC). The consortium is a collaboration of 25 US academic medical centres, teaching hospitals and other entities.

In conjunction, ONCURIOUS is working with BioInvent International AB as a development partner for this project.

((Comments on this story may be sent to

COPYRIGHT 2017 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2017 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Date:Jan 17, 2017
Previous Article:Benitec's BB-301 wins orphan drug designation in the EU for treating oculopharyngeal muscular dystrophy.
Next Article:Philogen granted IND approval by FDA for Phase 3 registration trial with investigational melanoma drug.

Terms of use | Privacy policy | Copyright © 2020 Farlex, Inc. | Feedback | For webmasters